- Mounjaro priced from Rs 14,000 for weekly administration.
- Offers six dose strengths for personalized treatment.
- Targets type 2 diabetes and obesity management.
Eli Lilly has launched Mounjaro in KwikPen format in India, a prefilled pen designed for weekly administration. The product is priced starting at Rs 14,000 and is intended for the treatment of type 2 diabetes and obesity. Mounjaro functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which means it helps regulate blood sugar levels and promotes weight loss. The medication is available only by prescription and should be used under medical supervision. The introduction of Mounjaro in India adds to the growing portfolio of diabetes treatments available in the region, which is facing a rising prevalence of diabetes and obesity. With six different dose strengths, Mounjaro allows healthcare providers to tailor treatment plans to individual patient needs, potentially improving adherence and outcomes.
Insights
This launch enhances treatment options for diabetes and obesity in India, addressing a significant health challenge.